CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Radial Versus Femoral Access for Rotational Atherectomy: A UK Observational Study of 8622 Patients Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management Management of No-Reflow Phenomenon in the Catheterization Laboratory Effect of Side Branch Predilation in Coronary Bifurcation Stenting With the Provisional Approach - Results From the COBIS (Coronary Bifurcation Stenting) II Registry Select Drug-Drug Interactions With Direct Oral Anticoagulants The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability Quantitative Assessment of Coronary Microvascular Function: Dynamic Single-Photon Emission Computed Tomography, Positron Emission Tomography, Ultrasound, Computed Tomography, and Magnetic Resonance Imaging Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials JACC Scientific Expert Panel Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization

Review Article2020 May 28.

JOURNAL:Heart Fail Rev. Article Link

The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus

D Farmakis, C Chrysohoou, G Giamouzis et al. Keywords: AF; direct oral anticoagulants; HF; non-vitamin k antagonist oral anticoagulants; rate control; rhythm control

ABSTRACT

Heart failure (HF) and atrial fibrillation (AF) often coexist, being closely interrelated as the one increases the prevalence and incidence and worsens the prognosis of the other. Their frequent coexistence raises several challenges, including under-diagnosis of HF with preserved ejection fraction in AF and of AF in HF, characterization and diagnosis of atrial cardiomyopathy, target and impact of rate control therapy on outcomes, optimal rhythm control strategy in the era of catheter ablation, HF-related thromboembolic risk and management of anticoagulation in patients with comorbidities, such as chronic kidney disease or transient renal function worsening, coronary artery disease or acute coronary syndromes, valvular or structural heart disease interventions and cancer. In the present document, derived by an expert panel meeting, we sought to focus on the above challenging issues, outlining the existing evidence and identifying gaps in knowledge that need to be addressed.